PIONEERING BREAKTHROUGH TREATMENTS FOR ARRYTHMIA

That are both highly efficacious and very safe

Arrythmias affect more than 2% of all individuals, with an incidence similar to stroke, myocardial infarction and heart failure

ADDRESSING A HUGE UNMET NEED

Regain control over their lives, without fear

DEDICATED TO HELPING ARRYTHMIA PATIENTS

Our Goal anD Vision

Bring to the patient with heart problems the scientific development carried out in an academic framework. Developing xanthohumol and the patented derivatives to treat atrial fibrillation (AFib), and the associated risks will allow us to do that.

AFib is the most common type of cardiac arrhythmia and its prevalence represents a 21st-century cardiovascular disease epidemic. The expected increase in global life expectancy means that the challenge of AF will only increase in coming years.

ARRhYTHMIAS AND ATRIAL FIBRILLATION (AFib)

AF or AFib, is the most common type of cardiac arrhythmia and its prevalence represents a 21st-century cardiovascular disease epidemic. The expected increase in global life expectancy means that the challenge of AFib will only increase in coming years.

The prevalence of AFib increased 3-fold over the last 50 years in the US and The Global Burden of Disease (GBD) 2019 estimated a worldwide prevalence of AFib around 59,7 million individuals in 2019.

Lifetime risk for the development of AFib is 25% for men and women of 40 years of age and older and this risk rises to more than 66% in individuals with at least one elevated risk factor, which include smoking, alcohol intake, sleep apnea, hypertension, obesity and diabetes.

Around 33% of the total AFib population is asymptomatic and in one study stroke was the first detected clinical manifestation of AFib in patients under 75 years of age . The European Society of Cardiology estimates that 20% to 30% of strokes are caused by AFib,and AFib caused strokes have a worse outcome than those not caused by AFib. In patients with AFib, a meta-analysis has shown that a 2.7-fold risk of dementia after the first or recurrent stroke exists.

The prevalence, cost (0.28% to 2.6% of all healthcare spending in European countries), demographics and the impact of quality of life on AFib patients mean that better therapeutic options are an absolute health priority.

What happens during Afib?

At the cellular level AFib starts in the form of abnormal electrical activity (early or late after depolarizations (EADs and DADs).

The normal beating in the upper chambers of the heart (the two atria) is irregular.

Blood doesn’t flow as well as it should from the atria to the lower chambers of the heart (the two ventricles).

About Xanthohumol

Xanthohumol is the principal prenylated flavonoid in hops (Humulus lupulus) and has been used as a sedative and relaxant since ancient times.

More recent research has highlighted the potential role for xanthohumol in the treatment of diverse pathologies including cancer, metabolic syndrome, diabetes, hepatitis and more.

In addition, xanthohumol is one of the most powerful antioxidants in nature and it´s particular antioxidant properties, as well as its ability to accumulate in mitochondria, allows it to suppress the spontaneous activity in cardiac cells which give rise to arrythmias, including AFib. In addition, it is known to have anti-inflammatory, antibacterial, antiviral, antifungal, and antiplasmodial activity.

Xanthohumol has even been proposed as a potential therapy for Covid-19 infections.

We have a research strategy centered on Xanthohumol as a therapy for AFib and cardiovascular diseases. Our next step will be a proof-of-concept clinical trial in patients with AF.

Why Xanthohumol for AFib?

We found that xanthohumol selectively suppresses pro-arrhythmic spontaneous or stress-triggered activity in cardiac cells. This effect is selective, without altering other ion currents in vitro or producing side effects in humans at equivalent doses. In vivo, xanthohumol shows effective cardiac regulation of different targets affected by arrhythmic processes as: inflammation, oxidative stress, right ventricle remodeling, hypertrophy, fibrosis and cell death in the heart.

Development of Xanthohumol Cardiac applications

In addition

Xanthohumol also exerts anticoagulant actions at the vascular level, as it effectively prevented venous and arterial thrombosis by inhibiting platelet activation and aggregation.

In addition, xanthohumol reduced pro-arrhythmic risk factors of AFib, such as hyperglycemia, obesity, hyperlipidemia and aging. These components are not only known to be associated with AFib development, but also impact the outcome of ablative therapy in AFib.

TEAM

Andrea Natale, MD, FACC

Clinical Advisor

Executive Medical Director
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.

Juan José Arnáiz Cot. PharmD, PhD

Co-Founder, CEO, COO

Sanghamitra Mohanty, MD, MS, FHRS

Clinical Advisor

Director of Research
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.

Lars Cleemann. PhD

Co-Founder

Associate Professor – Medical University of South Carolina

Luis Gandía, MD, PhD

Advisor

Full Professor of Pharmacology and
Chairman of the Department of Pharmacology and Therapeutics, Universidad Autónoma de Madrid.

Fred Stevens, PharmD, PhD

CSO

Ava Helen Pauling Professor and Associate Director of Research, Linus Pauling Institute
Professor, Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University.

Our Goal anD Vision

ARRhYTHMIAS AND ATRIAL FIBRILLATION (AFib)

What happens during Afib?

About Xanthohumol

Why Xanthohumol for AFib?

In addition

TEAM

NEWS

Creation of XanthoPharm advisory board

XanthoPharm expands its Scientific Advisory Board

XanthoPharm expands again its Scientific Advisory Board